AIM
ADVM

Aigen Investment Management’s Adverum Biotechnologies ADVM Stock Holding History

Aigen Investment Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,587
Closed -$172K – 597
2020
Q4 		$172K Sell
1,587
-1,437
-48% -$178K 0.02% 699
2020
Q3 		$311K Buy
+3,024
New +$453K 0.04% 527

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aigen Investment Management's ADVM Position: Q1 2021 in Review

Aigen Investment Management sold out of Adverum Biotechnologies (ADVM) in Q1 2021, closing a stake of 1,587 shares — an estimated $172K sold.

Aigen Investment Management first reported a position in ADVM in Q3 2020 and held it in 2 quarters. The position peaked at $311K in Q3 2020. 132 funds tracked by Wall St. Rank hold ADVM as of Q1 2021.

  • Aigen Investment Management reported no remaining Adverum Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • Aigen Investment Management sold 1,587 Adverum Biotechnologies shares in Q1 2021, an estimated $172K.
  • Aigen Investment Management first reported a position in Adverum Biotechnologies in Q3 2020 and held it in 2 quarters.
  • Aigen Investment Management's Adverum Biotechnologies position peaked at $311K in Q3 2020.
  • 132 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2021.

Based on Aigen Investment Management's 13F filing for Q1 2021, filed 11 May 2021.